RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA

Clinical trials for RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA trials appear

Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 2

Scientists test new drug duo to target Tough-to-Treat gynecologic cancers

Disease control Recruiting now

This early-stage study is testing a new combination of two oral drugs, M1774 and ZEN-3694, for women with recurrent ovarian or endometrial cancer. The main goals are to find the safest and most effective dose and to see how well the drugs work together to stop cancer cell growth.…

Matched conditions: RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 23, 2026 15:18 UTC

RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA

Get alerted when new RECURRENT ENDOMETRIAL CLEAR CELL ADENOCARCINOMA trials appear

Scientists test new drug duo to target Tough-to-Treat gynecologic cancers